Senior Manager, Pipeline Decision Analytics Team
Posted on: 22 Oct 2021
Cambridge, MA
Job Description
Job Description
In partnership with functions, Finance, and IT, this role will provide algorithm development to support R&D functions with their need to resource appropriately against the demands of the R&D drug portfolio. They will be accountable for ensuring the business process to collect, manage, and report on portfolio & resource data is predictable, effective, and high quality. They will work with other members of the Pipeline Decision Analytics team to ensure portfolio reporting and resource analytics meet the decision support needs of the most senior stakeholders in the R&D.
Specific responsibilities will include:
Drive data quality and algorithm development Lead the efforts to completion, inclusive of managing stakeholders, schedule, and change management.
Partners with the R&D PMO, Governance, Business Operations, Finance, IT and R&D functions, to drive business process improvements that improve data accuracy, and increase both a holistic portfolio view of the data, and utility of the data to inform RDLT-level decision-making
Qualifications
Bachelor’s Degree required, preferably in Life Sciences, Biology/Biotech. Master’s in a technical discipline or MBA is preferred.
5 years in a project management, portfolio management, or operations role, ideally in the Biopharma R&D space.
Direct knowledge of and experience with Planisware project management and resource management functionality.
Familiarity with Planisware as a vendor, particularly with regard to its support practices and policies.
Proficient in algorithm development, and data visualization software (Power BI and Tableau)
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
